In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pulling Back The Curtain On Biopharma Partnering In Cell And Gene Therapies

Janssen, Biogen And Astellas Execs Discuss Portfolio Priorities

Executive Summary

Therapeutic areas and unmet needs drive big company decision-making about when and what technologies to bring in from external sources, executives explained during a panel at the 2020 Cell and Gene Therapy Meeting on the Mesa.

You may also be interested in...



Anti-BCMA Therapies Aim To Raise The Bar In Myeloma

GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.

Biogen By Buying Nightstar Targets Ophthalmology As Emerging Growth Area

Biogen is paying around $800m cash to buy UK-based Nightstar Therapeutics, which focuses on gene therapy for retinal diseases.

Biogen/Ionis’s Spinraza Approved; Second Antisense Drug For Neurodegeneration In 2016

Analysts expect strong uptake for the antisense oligonucleotide (ASO) given the high unmet need in SMA and positive data in multiple studies, while the first ASO approved this year – Sarepta’s Exondys 51 – has seen some pushback from payers despite the lack of DMD therapies.

Topics

Related Companies

UsernamePublicRestriction

Register

OM003971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel